Pacific Biosciences of California, Inc. has a 52-week low of $1.16 and a 52-week high of $5.01. The company has a market cap of $366.98 million, a price-to-earnings ratio of -0.82 and a beta of 1.92.

In the last three months, 4 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find ...

PACB stock opened at $1.56 on Tuesday. Pacific Biosciences of California has a 12-month low of $1.16 and a 12-month high of $6.09. The company has a quick ratio of 8.64, a current ratio of 9.74 ...

Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2.00. The company’s shares closed yesterday at $1.32.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51 ...

SUGAR LAND, Texas--(BUSINESS WIRE)--FDA has authorized Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for use in the first pediatric clinical trial, to evaluate if ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...